

AD_____

Award Number: W81XWH-€ ÆÆ€G Æ

TITLE: Ô@&][ã Áæ@ æ• ÁBçæ^áÀ^ Ä^Ë^| Ææ } Æ Á^æ æÔæ &^ Á^||

PRINCIPAL INVESTIGATOR: Răzvan

CONTRACTING ORGANIZATION: University of Xä* ä æ
 Á@æ[¢•cä^ÊXOÄGG€ Á

REPORT DATE: T æ ÁGFF

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-05-2011		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 MAY 2010-30 APR 2011	
4. TITLE AND SUBTITLE Checkpoint Pathways Activated by Re-Replication in Breast Cancer Cells				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0286	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jie Lin E-Mail: j19sj@virginia.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Virginia Charlottesville, VA 22904				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Emi-1 has been known as an inhibitor of APC (anaphase promoting complex). The depletion of Emi-1 would prematurely activate APC, lead to simultaneous degradation of geminin and cyclin A, and induce re-replication at least in colon cancer cell lines and breast epithelial cell MCF10A. We proposed Emi-1 depletion can induce re-replication in breast cancer cells, lead to gene amplification and stimulate tumor growth. We showed earlier that the depletion of Emi-1 induced re-replication and activated the checkpoint pathway in several breast cancer cell lines. However, we didn't observe any difference on cell growth after methotrexate (MTX) inhibition, as an indicator of gene amplification, between control and re-replicated cells, with or without the inhibition of checkpoint and apoptosis pathways. We didn't observe significant difference in tumor growth in xenograft experiments using those cells. In a separate study, we found that re-replication in colon cancer cells could activate not only apoptosis but also cellular senescence. So we hypothesize that re-replicated cells underwent senescence before we could detect any gene amplification phenotype. To test this hypothesis, we tried to inhibit the senescence pathway by depleting several known important genes. However, those genes are not essential for senescence activation. Further studies are necessary to address the issue.					
15. SUBJECT TERMS Emi-1, re-replication, senescence, checkpoint, MLN4924, gene amplification					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 49	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	9
References.....	9
Appendices.....	11

Introduction

Replication of chromosomal DNA is a key event in the cell cycle. Chromosomes must be replicated precisely once per cell cycle. Both initiation of replication and prevention of re-replication in the same cell cycle are under the control of CDKs (1-3). However, the discovery of geminin in metazoans as an inhibitor of pre-replicative complex (pre-RC) formation indicated that not all mechanisms preventing inappropriate pre-RC formation are mediated by elevated CDK activity. Geminin accumulates during S phase until late M phase when it is degraded in an APC-dependent manner. Studies of DNA replication of either chromosomes or episomes support a role for geminin in preventing pre-RC assembly in cancer cells (4-6).

Although the role of geminin in preventing re-replication was well demonstrated in lung and colon cancer cells (7), we had difficulty observing re-replication in non-malignant breast epithelial cells with geminin depletion alone. Only one breast cancer cell line (HCC1937 stably transfected with BRCA1 to correct the original BRCA1 mutation) shows re-replication upon geminin depletion (8, 9). We reasoned that the breast epithelial cells had another pathway to prevent re-replication in addition to a geminin-dependent pathway. Since cyclin A/cdk2 activity is known to prevent re-licensing of origins, we explored whether the combined removal of geminin and cyclin A (and perhaps a few other proteins) can be affected in S phase. Both cyclin A and geminin are substrates of the APC (anaphase promoting complex), an E3 ligase that is normally active in mitosis. APC is kept in an inhibited state by an F-box containing protein, Emi1 (10, 11). We reasoned that depletion of Emi1 in S phase cells would prematurely activate APC and lead to the simultaneous degradation of geminin and cyclin A. Indeed, in MCF10A breast epithelial cells, Emi1 depletion induces DNA re-replication (12).

A checkpoint response activated by DNA damage is the foundation of genomic stability. It rapidly transduces the damage signals to arrest the cell cycle and activates the DNA repair machinery. Checkpoint pathways involve several groups of proteins, which include DNA damage sensors to detect the damage signal, signal transducers to amplify the signal and effectors to block the cell cycle and activate repair process (13, 14). In previous research from the Dutta lab, it was shown that Geminin depletion in human colon and lung cancer cells causes re-replication and activates a G2/M checkpoint (4, 8, 9, 15). In HCT116 colon cancer cells, suppression of ATR or Chk1, together with Geminin knockdown, decreases checkpoint activation and re-replication (9, 16).

In particular we have hypothesized that re-replication can lead to the gene amplification that is prevalent in breast cancers and stimulate xenografted tumor growth in nude mice. The finding that Emi1 depletion induces re-replication in MCF10A breast epithelial cells has made it possible for us to test this hypothesis. However, we didn't observe any difference on cell growth after methotrexate (MTX) inhibition, as an indicator of gene amplification, between control and re-replicated cells, with or without the inhibition of checkpoint and apoptosis pathways. In addition, we used those cells (control and re-replicated, with or without MTX addition) in xenograft experiments and no significant difference in tumor growth was observed. In a separate study, we found that re-replication in colon cancer cells could activate not only apoptosis but also cellular

senescence. So we hypothesize that re-replicated cells underwent senescence before we could detect any gene amplification phenotype. To test this hypothesis, we will inhibit the senescence pathway together with the checkpoint and apoptosis pathways to induce gene amplification.

Body

Both p21 and p53 are important but not essential in activating senescence pathway after re-replication

Both p53 and p21 can have a function in the cellular senescence pathway (17, 18). We therefore examined protein expression levels of p53 and p21 over 8 days following an 8-hour treatment with MLN4924. Both p53 and p21 were induced 24 hour post-wash-out and their expression persisted thereafter for the entire time course (Fig. 1A). We then performed the SA- β -gal staining assay in p53^{-/-} or p21^{-/-} HCT116 cells to determine the level of senescence in the absence of these proteins. As shown in Fig. 1B, the number of SA- β -gal stained cells was only half in the p21^{-/-} HCT116 compared to those of WT HCT116, indicating that p21 plays an important role in the senescence pathway. p53 appeared to be less essential than p21, which was consistent with results from other studies (19). The p16 gene is silenced in these cells (20), so the residual senescence in the p21^{-/-} cells was most likely by a p21- and p16- independent pathway.

p21 and p53 deficient HCT116 cells are more sensitive to transient treatment with MLN4924

The senescence pathway is still active after depletion of p53 and p21 in HCT116 cells, which makes it difficult to test whether gene amplification can be induced by re-replication in this scenario. Therefore, we decide to focus on the therapy effect of the new anti-cancer drug MLN4924.

Since transient exposure to MLN4924 causes both senescence and apoptosis, but senescence is attenuated in the p21^{-/-} cells, we could ask how important is the senescence for the toxicity of MLN4924 on cancer cells. We noticed that although p21- and p53-deficient cells exhibited less senescence after transient treatment with MLN4924, the total cell numbers observed were much less than in WT cells, which suggested that p53^{-/-} or p21^{-/-} HCT116 cells might be more susceptible to overall cell death or growth inhibition by MLN4924. Colony formation assays following an 8-hour treatment of MLN4924 in all three cell-lines confirmed this (Fig. 2A). The cell growth was decreased by MLN4924 treatment in a dose-dependent manner in WT HCT116 cells, but the p53- and p21- deficient cells formed fewer colonies than WT cells, indicating that the absence of p53 or p21 sensitized the cells to the drug treatment. Since senescence is attenuated in the mutant cells (Fig. 1B), the result suggests that apoptosis pathways are important for cell killing after transient exposure to MLN4924.

We also performed an MTT cell growth assay to compare cell survival rate upon either transient or 72-hour continuous exposure to MLN4924. After 8-hour treatment, the IC₅₀ for WT, p53^{-/-} and p21^{-/-} cells were 0.9 μ M, 0.18 μ M and 0.25 μ M, respectively (Fig.

2B), which was consistent with the results of the colony formation assays. However, the difference was much smaller upon 72-hour continuous exposure: IC_{50} of $0.08\mu M$, $0.07\mu M$ and $0.07\mu M$ in WT, p53^{-/-} and p21^{-/-} cells, respectively (Fig. 2C).

P53 is one of the factors that affect MLN4924 induced cell death

To confirm that cells with mutant p53 were more susceptible to cell death by MLN4924, we performed MTT assay in breast cancer cells MCF7 after MLN4924 transient exposure. After p53 knockdown, IC_{50} decreased from $0.68\mu M$ to $0.4\mu M$ (Fig 2B, 3A). Similar results were obtained when we compared IC_{50} in two lung cancer cells NCI-H23 (p53 mutant, IC_{50} $0.28\mu M$) and NCI-H460 (wild type p53, IC_{50} $1.5\mu M$) (Fig 2B). Intriguingly, when we compared IC_{50} in more than 20 cancer cell lines upon 72hr MLN4924 treatment, after dividing them into p53 WT (wild type) group and p53 MT (mutant) group, we found the median value of WT group was significantly higher than MT group ($465nM$ vs. $280nM$, Fig. 3B) despite all the different genetic backgrounds. It must be noted, however, that there are other genetic factors that affect MLN4924 sensitivity besides p53 status. For example we obtained opposite results when comparing MCF7 (WT p53) with MDA-MB-231 (MT p53) cells where the MCF7 cells were more susceptible to MLN4924 (Fig. 3C). Despite this exception, our data suggests that p53 mutant cells are generally more susceptible to MLN4924.

Thus there is a clear therapeutic advantage of transient MLN4924 treatment, particularly considering that the p53 mutant cells are more susceptible to cell death than the p53 WT cells. Since up to 50% of human tumors have a mutant p53 gene, our results suggest that the kinetics of MLN4924 administration might alter the therapeutic index.

In summary, I have finished the following tasks in the proposal so far.

I. Task 1: To investigate whether Emi-1 depletion could induce re-replication and checkpoint activation in several breast cancer cell lines

a) Culture different breast cancer cell lines with appropriate growth media.

b) Perform siRNA transfection to diminish Emi-1 level in these cells and examine the extent of DNA re-replication by FACS assay.

c) Examine Chk1 and Cdc2 phosphorylation in Emi-1 depleted breast cancer cells.

II. Task 2: To examine whether transient siRNA of Emi-1 leads to increased susceptibility to DHFR gene amplification

a) Perform siRNA against Emi-1 in MCF10A, T47D, MDA-MB-468 and Sk-br-3 cells, grow the above cells under selection of methotrexate and determine cell growth after methotrexate inhibition.

c) Bypass checkpoint pathways with UCN-01 and inhibit apoptosis with Z-VAD-FMK in the above cells and perform methotrexate selection experiment.

III. Task 3: To examine whether the loss of Emi1 in breast cancer cells will stimulate tumor growth in animal model experiments.

c) Cells transiently transfected with Emi1 or control (GL2) and cultured in MTX containing medium were injected into nude mice. Xenograft experiments were performed.

Key research accomplishments

1. Observed re-replication in MCF10A breast epithelial cell, Sk-Br-3 and T47D breast tumor cells.
2. Confirmed checkpoint pathway activation in re-replicated breast cancer cells.
3. Found no difference in methotrexate resistance between control and re-replicated breast cancer cells.
4. Found no difference in methotrexate resistance between control and re-replicated breast cancer cells after the bypass of checkpoint activation and apoptotic pathways.
5. Found requirement for microenvironment for T47D, MDA-MB-468 and Sk-Br-3 cells to proliferate well
6. Found no significant different in tumor growth between xenografts of control and re-replicated cell, with or without MTX addition.
7. Found senescence induction upon re-replication.
8. Found p21 and p53 are important but not essential genes in senescence pathway in MLN4924 treated HCT116 cells.
9. Found p53 is an important factor to affect MLN4924 induced cell death in all cancer cells including breast cancer cells.

Reportable outcomes

1. Cancer Research paper, “NEDD8 targeting drug MLN4924 elicits DNA re-replication by stabilizing Cdt1 in S Phase, triggering checkpoint activation, apoptosis and senescence in cancer cells”. (First Author.)

Conclusions

P53 and p21 are both important but not essential in re-replication activated senescence pathway. Although it is difficult to test the hypothesis that re-replication can induce gene amplification after DNA re-replication in this scenario, we evaluated the importance of p53 in the cancer therapy of MLN4924. And we found p53 is an important factor to affect MLN4924 induced cell death in breast cancer cells.

Reference

1. Nurse P. Ordering S phase and M phase in the cell cycle. *Cell* 1994;79:547-50.
2. Nasmyth K. At the heart of the budding yeast cell cycle. *Trends Genet* 1996;12:405-12.
3. Wuarin J, Buck V, Nurse P, Millar JB. Stable association of mitotic cyclin B/Cdc2 to replication origins prevents endoreduplication. *Cell* 2002;111:419-31.
4. Dhar SK, Yoshida K, Machida Y, et al. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. *Cell* 2001;106:287-96.
5. Takeda DY, Shibata Y, Parvin JD, Dutta A. Recruitment of ORC or CDC6 to DNA is sufficient to create an artificial origin of replication in mammalian cells. *Genes Dev* 2005;19:2827-36.
6. McGarry TJ, Kirschner MW. Geminin, an inhibitor of DNA replication, is degraded during mitosis. *Cell* 1998;93:1043-53.
7. Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Walter JC, Dutta A. Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. *Science* 2000;290:2309-12.
8. Tada S, Li A, Maiorano D, Mechali M, Blow JJ. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. *Nat Cell Biol* 2001;3:107-13.
9. Zhu W DA. An ATR- and BRCA1-Mediated Fanconi Anemia Pathway Is Required for Activating the G2/M Checkpoint and DNA Damage Repair upon Rereplication. *MCB* 2006;26.
10. Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK. Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. *Cell* 2001;105:645-55.
11. Hsu JY, Reimann JD, Sorensen CS, Lukas J, Jackson PK. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). *Nat Cell Biol* 2002;4:358-66.
12. Machida YJ, Dutta A. The APC/C inhibitor, Emi1, is essential for prevention of rereplication. *Genes Dev* 2007;21:184-94.
13. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu Rev Biochem* 2004;73:39-85.
14. Niida H, Nakanishi M. DNA damage checkpoints in mammals. *Mutagenesis* 2006;21:3-9.

15. Zhu W, Chen Y, Dutta A. Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. *Mol Cell Biol* 2004;24:7140-50.
16. Lin JJ, Dutta A. ATR pathway is the primary pathway for activating G2/M checkpoint induction after re-replication. *J Biol Chem* 2007;282:30357-62.
17. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 1997;88:593-602.
18. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. *Mol Cell Biol* 1999;19:2109-17.
19. Zou X, Ray D, Aziyu A, et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. *Genes Dev* 2002;16:2923-34.
20. Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. *Cancer Res* 1998;58:591-3.
21. Hermanns J, Schulze A, Jansen-Db1urr P, Kleinschmidt JA, Schmidt R, zur Hausen H. Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins. *J Virol* 1997;71:6020-7.

Appendices

1. Cancer Research Paper:

NEDD8 targeting drug MLN4924 elicits DNA re-replication by stabilizing Cdt1 in S Phase, triggering checkpoint activation, apoptosis and senescence in cancer cells

Jie Jessie Lin¹, Michael A. Milhollen², Peter G. Smith², Usha Narayanan², Anindya Dutta^{1*}

1. Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22903 USA

2. Discovery, Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, USA

Running Title: Effect of Transient Exposure of HCT116 to MLN4924

Keywords: MLN4924, re-replication, senescence

This work was supported by the Research Project Grant from National Institutes of Health (R01-CA60499 and CA89406). Jie Lin is supported by the Predoctoral Traineeship Award from Department of Defense Breast Cancer Research Program (W81XWH-08-1-0286).

* Corresponding author. Mailing address: Box 800733, Jordan 1240, 1300 Jefferson Park Ave, University of Virginia School of Medicine, Charlottesville, VA 22908. Phone: (434)-924-1227. Fax: (434)-924-5069. Email: ad8q@virginia.edu

Precis: Findings reveal insights into the mechanism of action of an important new drug in clinical trials, also showing that even transient exposure to p53 mutant cancer cells may be sufficient to produce potent anticancer effects.

Abstract

MLN4924 is a first-in-class experimental cancer drug that inhibits the NEDD8-activating enzyme, thereby inhibiting cullin-RING E3 ubiquitin ligases and stabilizing many cullin substrates. The mechanism by which MLN4924 inhibits cancer cell proliferation has not been defined, although it is accompanied by DNA re-replication and attendant DNA damage. Here we show that stabilization of the DNA replication factor Cdt1, a substrate of Cullins 1 and 4, is critical for MLN4924 to trigger DNA re-replication and inhibit cell proliferation. Even only one hour of exposure to MLN4924, which was sufficient to elevate Cdt1 for 4-5 hours, was found to be sufficient to induce DNA re-replication and to activate apoptosis and senescence pathways. Cells in S phase were most susceptible, suggesting that MLN4924 will be most toxic on highly proliferating cancers. Although MLN4924-induced cell senescence appears to be dependent on induction of p53 and its downstream effector p21^{Waf1}, we found that p53^{-/-} and p21^{-/-} cells were even more susceptible than wild-type cells to MLN4924. Our results suggested that apoptosis, not senescence, may be more important for the anti-proliferative effect of MLN4924. Further, our findings show that transient exposure to this new investigational drug should be useful for controlling p53-negative cancer cells, which often pose significant clinical challenge.

Introduction

Duplication of the genetic material is a key event in the cell cycle. In eukaryotes, replication origins are recognized and bound by a six-subunit complex called ORC (Origin Recognizing Complex) (1-3). Cdc6 and Cdt1 are subsequently recruited independently to those sites in late M or early G1 phase (1, 3, 4), followed by the

recruitment of MCM2-7 complex to initiate DNA replication (5, 6). It is vitally important that the initiation of replication at replication origins is tightly controlled such that it occurs only once during the cell cycle. Mammalian cells have developed different mechanisms to prevent re-initiation and subsequent re-replication of DNA within the same cell cycle. One such mechanism is the inactivation of Cdt1 during S and G2 phases (7, 8). After replication initiation, Cdt1 is either inhibited by a small protein called Geminin (9, 10) or degraded by two distinct E3 ligases – cdk-dependent SCF^{skp2} and Cul4-DDB1^{cdt2} in S or G2/M phase (8, 11). Deregulation of those pathways by depletion of Geminin, Cul4 or Cdt2 activates (or stabilizes) Cdt1 and consequently induces DNA re-replication in different systems (7, 12-14).

Studies have shown that cullin-RING ligases (CRLs), a subclass of E3 ligases that includes both SCF^{skp2} and CRL4^{Cdt2}, are modified by an ubiquitin-like protein NEDD8, which subsequently facilitates their ligase activities (15-18). Thus, through the modulation of this activity, the NEDD8 pathway regulates the abundance of CRL substrates. MLN4924, a potential cancer drug currently in phase I clinical trials, is a small molecule inhibitor of NEDD8 activating enzyme (NAE) (19, 20). MLN4924 treatment in HCT116 human colon cancer-derived cell line inhibits NAE, and therefore the NEDD8 conjugation pathway, resulting in an increase in protein abundance of CRL substrates such as Cdt1 (21). This is accompanied by an increase in the percentage of cells containing more than 4N DNA, indicating DNA re-replication was occurring. Cells treated with MLN4924 also undergo significant apoptosis contributing to the drug's anti-proliferative activity. Various CRL substrates play critical functions in cellular growth

and survival pathways and the question remained as to which substrates are critical for MLN4924 induced re-replication and apoptosis.

In this paper, we examine whether Cdt1 is the key factor for the induction of DNA re-replication in HCT116 cells treated with MLN4924. Among the different approaches for stimulating Cdt1 activation, MLN4924 shares a similarity with that of Cdt2 depletion in inactivating the CRL4^{cdt2} E3 ligase, as opposed to Geminin depletion, which activates Cdt1 by a different pathway. We verified this hypothesis and detected a synergistic effect between MLN4924 treatment and Geminin depletion. Transient exposure of cells to MLN4924 led to DNA re-replication, as well as activation of the apoptosis and senescence pathways. This allowed us to test whether a specific part of the cell cycle was particularly susceptible or resistant to MLN4924. Finally, we compared the sensitivity of wild-type (WT) HCT116 cells and isogenic p53^{-/-} or p21^{-/-} HCT116 cells to MLN4924, and discovered that WT HCT116 cells were less susceptible to MLN4924 induced cell death. The results indicate that p53-deficient cancer cells may be more sensitive to MLN4924, emphasizing the therapeutic opportunity with this class of investigational drugs.

Materials and Methods

Cell Lines and Chemicals

Human colorectal cancer cell lines HCT116 (WT, p53^{-/-}, p21^{-/-}) were cultured in McCoy's 5A modified medium (HyClone) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. Isogenic p21^{-/-} and p53^{-/-} HCT116 cell lines were described earlier (22). Millennium Pharmaceuticals Inc provided MLN4924, which was

then dissolved in DMSO (Sigma). The concentration of Z-Vad-FMK (Calbiochem) used was 50 μ M. The concentration of Nocodazole (Sigma) used was 40ng/ml.

siRNA

Short interfering (siRNA) oligonucleotides (Invitrogen) were made to the following target sequences (sense): GL2 (control), AACGUACGCGGAAUACUUCGA; Cdt1, GCAAUGUUGGCCAGAUCAA; Cdc6, GAUCGACUUAUCAGGUAAU; Mcm7, GAUGUCCUGGACGUUUACA; Geminin (Gem), UGCCAACUCUGGAAUCAA (12); Cdt2, GAAUUAUACUGCUUAUCGA. Transfections were performed with 20nM siRNA oligonucleotide duplexes with Lipofectamine RNAiMAX (Invitrogen) according to the instructions of manufacturer.

Antibodies and immunoblotting

Rabbit anti Cdt1, rabbit anti-geminin, and rabbit anti-Cdt2 were raised as described (9, 23). The purchased antibodies were mouse anti-p21 (Lab vision/Neomarkers); mouse anti- β -actin, mouse anti-Chk1, mouse anti-Chk2 (Sigma); rabbit anti-Chk1-P-S317, rabbit anti-Chk2-P-T68; rabbit anti-PARP, rabbit anti-H3-P-S10 (Upstate). Cells were lysed as described (24), and western blot analysis was performed according to standard procedures.

Flow Cytometry Analysis (FACS)

Cells were harvested by trypsinization and fixed with 70% ethanol overnight at -80°C. Cells were then stained and analyzed as described before (12). For FACS analysis with both PI and BrdU double staining, cells were labeled with 10 μ M BrdU (Sigma) and then harvested as described earlier (12).

Timelapse Movie analysis

HCT116 cells were plated at 15,000 cells per well in 6-well culture plates (Becton Dickinson). For continuous treatment cells were treated with 1 μ M MLN4924 for 72 hours. For wash-out treatment HCT-116 cells were treated with 1 μ M MLN4924 for 8 hours then washed with fresh media to remove compound and maintained in fresh compound free media for 8 days. Timelapse movie images were taken at times indicated using an automated TE2000U microscope (Nikon Instruments, Melville, NY) with Hoffman-modulation optics, 20x objective, with environmental control, and an Orca-ER CCD camera (Hamamatsu, Bridgewater, NJ) controlled with MetaMorph imaging software (Molecular Devices, Downingtown, PA).

Measure Cell Growth and Clonogenicity

The number of viable cells was estimated with a cell proliferation assay (MTT) kit (Promega) according to the manufacturer's instructions. Cells were seeded into 96-well plates at 500 cells per well, treated with DMSO or MLN4924 and incubated for 7 days before MTT assay. Cell clonogenicity assay was performed as described (25). Cells were seeded into 6-well plates at 3*10³ cells per well. DMSO or 1 μ M MLN4924 were added for 8 hours. Cells were washed twice with PBS and incubated in fresh medium after the wash-out. Medium was changed every 2-3 days and the Colonies were stained with crystal violet to show cell clonogenicity. OD595 was measured to quantify cell colony numbers and normalized to DMSO treated control sample to obtain cell survival rate.

SA- β -gal Staining Assay for Senescence

Senescence β -galactosidase staining assay was performed in a 6-well plate with staining kit (Cell Signaling Technology, #9860). Cells were washed with PBS, fixed and stained following manufacturer's instruction. Stained plates were checked under a microscope

for development of blue color. For each sample, SA- β -gal positive and total cell numbers were counted from 5 different microscopic fields (roughly >200 cells per field).

Results

Stabilization of Cdt1 protein is critical for MLN4924-induced re-replication in HCT116 cells

Consistent with previous results (21), we observed re-replication after 20 hours of treatment of HCT116 cells with MLN4924 (Fig. 1A). To investigate whether the regulation of Cdt1 protein level plays a role in MLN4924-induced re-replication, HCT116 cells were treated with siRNA oligonucleotides targeting Cdt1 for 48 hours prior to the addition of MLN4924. After 20 hrs of MLN4924 treatment, Cdt1 protein level increased significantly as expected (Fig. 1B, lane 1,2) and more than 40% of cells were determined to have re-replicated, containing >4N DNA content. However, in the cells depleted of Cdt1 by siRNA, the percentage of re-replicating cells reduced to 15% (Fig. 1A). In these cells, Cdt1 protein expression was effectively repressed (Fig. 1B, lane 1,3 and 4), although at a higher exposure, Cdt1 protein level was observed to be modestly induced in MLN4924 treated cells (Fig. 1B, lane 3,4) indicating that the drug was still inhibiting its degradation, potentially explaining the 15% of cells with >4N DNA.

Re-replication has been shown to induce both single-strand and double-strand DNA breaks, resulting in activation of checkpoint pathways (24, 26). Indeed, we observed both Chk1 and Chk2 phosphorylation in MLN4924 treated cells (Fig. 1B, lane 1, 2). Cdt1 siRNA treatment not only decreased the percentage of cells undergoing re-replication, but also decreased the activation of Chk1 and Chk2 (Fig. 1B, lane 2, 4),

indicating that MLN4924 induces DNA damage primarily through Cdt1-dependent re-replication.

To characterize whether other replication initiators contribute to the re-replication induced by MLN4924, we systematically depleted other components of the pre-RC. We treated HCT116 cells hypomorphic for ORC2 (27) with MLN4924 and compared the extent of re-replication with that of WT cells. As shown before, although we could detect ORC2 in 6 μ g of extract from WT HCT116 cells, it was hard to detect ORC in even 60 μ g of e83 HCT116 cells (Fig. S1A). Despite this, there was no significant difference in the amount of re-replication between these cell types (Fig. 1C). Furthermore, we performed siRNA knockdown of both MCM7 and Cdc6 (Fig. S1B, S1C) and observed no difference in the amount of MLN4924 induced re-replication in both cases (Fig. 1D, 1E).

Interestingly, we noticed that MLN4924 treatment could also induce Cdc6 protein expression (Fig. S1C), which indicated that Cdc6 could be a potential CRL substrate.

Overall, these results demonstrate that the ubiquitin-dependent degradation of Cdt1 protein is the rate-limiting step in preventing re-replication, and that stabilization of this component of the pre-RC by MLN4924 induces re-replication in HCT116 cells. The re-replication leads to DNA damage and activates checkpoint pathways.

MLN4924 induces re-replication through the inhibition of CRL4^{Cdt2}

Because MLN4924 functions as a NAE inhibitor (21), it is expected to inhibit all cullins, including Cul1 and Cul4 ubiquitin ligases known to degrade Cdt1 (28-32). Cdt2 depletion, and thus inactivation of CRL4^{Cdt2}, in zebra fish, xenopus egg extracts and human cancer cells induces DNA re-replication (13, 33). If CRL4^{Cdt2} inhibition is the

primary mechanism by which MLN4924 causes re-replication, one would predict that there should be no synergy between MLN4924 and siCdt2 in induction of re-replication.

To determine whether MLN4924 acts through the same mechanism to induce re-replication as that of Cdt2 depletion, we compared the Cdt1 protein level in cells depleted of Cdt2 by siRNA or treated with MLN4924. As seen in Figure 2A, Cdt2 depletion caused less Cdt1 accumulation than MLN4924 alone (Fig. 2A, lane 2 and 3) and together the two stabilized Cdt1 more (lane 4). However, the extent of re-replication caused by siCdt2 was more than that observed in cells treated with MLN4924 alone, and adding the two together did not increase re-replication (Figure 2B). This suggests that (a) pure CRL4^{Cdt2} inhibition with siCdt2 is more effective at inducing re-replication than inhibiting all cullins by MLN4924, but (b) once Cdt1 level has crossed a certain threshold, there is no further increase in re-replication with more Cdt1. In addition, other substrates/pathways affected by MLN4924 may make cells die, thereby decreasing the extent of re-replication observed.

In contrast to the lack of synergy in induction of re-replication by siCdt1 + MLN4924, siGeminin (to activate Cdt1 in S through G2 phase) + MLN4924 caused more re-replication than either agent alone. This is particularly evident when one consider the proportion of cells with >6N DNA content (Fig. 2B).

These results suggest that removal of an inhibitor of Cdt1 (Geminin) will act additively with stabilization of Cdt1 by MLN4924 to cause more re-replication. In contrast, inhibition of CRL4^{Cdt2} by siCdt2 and MLN4924 does not additively cause more re-replication, even though there was more stabilization of Cdt1. This result is consistent

with the hypothesis that MLN4924 causes re-replication primarily through the inhibition of CRL4^{cdt2}.

Transient exposure of HCT116 cells to MLN4924 induces re-replication

One advantage of using MLN4924 treatment to induce re-replication lies in its ability to act rapidly. Previous studies have shown that in as little as 5 minutes following MLN4924 treatment, the NEDD8 pathway is inhibited concurrent with the accumulation of Cdt1 protein (20, 21). Therefore we wanted to test whether transient treatment of MLN4924 is sufficient to induce re-replication in HCT116 cells.

Surprisingly, as shown in Fig. 3A, one-hour exposure to MLN4924 was sufficient to induce re-replication in 40% of the cells. The percentage of cells with re-replication increased with longer pulse of MLN4924, but was close to its maximum after 4 or 8 hours of treatment, with 60 % of cells re-replicating their DNA.

To determine the rate of Cdt1 turnover following MLN4924 wash-out, we treated HCT116 cells with MLN4924 for 4 hours, and harvested the cells after different time periods. Cdt1 protein level increased following MLN4924 treatment (Fig. 3B, W0). However, by 4 hours after wash-out, Cdt1 level decreased to basal levels (Fig. 3B, W4). These results indicate that although Cdt1 stability returns to normal in roughly 4 hours after the removal of MLN4924, this short period of Cdt1 stabilization is sufficient to induce irreversible DNA re-replication.

S phase cells are more susceptible to MLN4924 induced re-replication

Since a mere 4-hour pulse treatment of MLN4924 leads to re-replication, we decided to test which portion of the cell cycle was more susceptible to the drug exposure. HCT116 cells synchronized by nocodazole block/mitotic shake-off were exposed to

MLN4924 at the indicated times post-mitosis (Fig. 4A). Cells were then collected for flow cytometry analysis (FACS). As shown in Fig. 4B, cells started to enter G1 around 4 hours after nocodazole release and began S phase after approximately 12 hours. This suggests that the majority of the cells were in M-G1 at T4 and in either S phase or at the G1/S transition at T12. We saw a similar increase in Cdt1 protein level after MLN4924 treatment in both populations (Fig. 4C). However, whereas only 10% of the cells re-replicated when Cdt1 was stabilized in M-G1 phase cells, 50% of the cells showed re-replication upon stabilization of Cdt1 in S phase cells (Fig. 4D). These results demonstrate that S phase cells are more susceptible to MLN4924-induced DNA re-replication.

To ask whether cells must be in S-phase for MLN4924 to induce re-replication, we labeled the cells with bromodeoxyuridine (BrdU) for 40 minutes to mark cells in active S phase, washed out BrdU and added MLN4924 for 4 hours. Cells were collected for FACS after 20 hours (Fig. 4E). BrdU positive cells, which were actively replicating when exposed to MLN4924, showed 44% of cells re-replicating, whereas only 14% of the BrdU negative cells re-replicated (Fig. 4F). These results further demonstrate that actively replicating cells are more susceptible to MLN4924-induced re-replication.

Both checkpoint and apoptosis pathways are activated upon short exposure of cells to MLN4924

Re-replication induces DNA damage and checkpoint activation (24, 26, 34). The initiation of DNA re-replication by a short exposure to MLN4924 led us to test whether checkpoint pathways were similarly activated in those cells. We treated HCT116 cells with MLN4924 for 8 hours and harvested cells 24 or 72 hours after wash-out. Chk1 was

activated 24 hours after drug wash-out while DNA re-replication was seen in 30 to 55% of cells (at 1 and 3 μ M MLN4924, respectively). The DNA damage checkpoint pathway still persisted even at 72 hours after wash-out, when re-replication was observed in 10 to 25% of cells (Fig. 5A, 5B). In addition, we noticed that PARP cleavage happened only at the later time point, suggesting that apoptosis was not activated until 72 hours after wash-out. This was further confirmed by the increase of sub-G1 population cells (Fig. 5B). Overall, these results were consistent with the idea that even transient exposure of MLN4924 leads to re-replication, activates checkpoint pathways and eventually induces apoptosis following irreparable DNA damage.

Senescence is induced after transient exposure to MLN4924 through the induction of p53 and p21

When culturing cells after transient exposure to MLN4924, we noticed changes in cell morphology starting approximately 72 hours post-wash-out, including an increase in cell size, intracellular vesicle accumulation and flatness. As shown in the upper panel of Fig. 6A, after 48 hours or more of continuous exposure to MLN4924, cells shrank and became round, suggesting those cells were undergoing apoptosis. However, after a transient 8-hour exposure to MLN4924, cells exhibited the flattened, vesiculated morphology, often noticed when cellular senescence pathway is activated.

Senescence is marked by permanent withdrawal from the cell cycle. To test whether MLN4924 induces senescence, we first performed colony formation assays to determine the clonogenicity of the cells (35). We added MLN4924 to HCT116 cells for 8 hours and cultured cells for 7 days after wash-out for colony formation as measured by crystal violet staining (Fig. S2A). Quantitation of the optical density of staining (Fig. 6B)

showed that MLN4924 treatment suppressed the clonogenicity, a characteristic of senescent cells.

Senescence Associated β -gal (SA- β -gal) staining is a well-accepted biomarker of senescence (36). Transient treatment of cells with MLN4924 increased the percentage of re-replicating cells (Fig. 3A) and the percentage of SA- β -gal staining (Fig. 6C, 6D). This suggested that the senescence pathway was activated upon transient exposure to MLN4924. These results were consistent with the earlier findings that re-replication can activate the DNA damage response leading to cellular senescence (37).

We next examined whether reduction of re-replication by Cdt1 depletion could decrease senescence following MLN4924 treatment. We performed a similar assay as that displayed in Fig. 1A, except that the HCT116 cells were exposed to MLN4924 for only 8 hours and cells collected for FACS after 24 hours or SA- β -gal staining after 72 hours (Fig. 6E). Consistent with our hypothesis, Cdt1 depletion reduced both re-replication and senescence to a similar degree. Together, these data suggest that re-replication induced by transient exposure to MLN4924 leads to senescence. 8 hr exposure to MLN4924 also induced apoptosis, as measured by the cleavage of PARP (Fig. 5A). Thus transient treatment with MLN4924 induces senescence or apoptosis (also evident in Fig. 6A, 72hr/WO), while continuous treatment with the drug leads mostly to apoptosis (Fig. 6A, 72 hrs).

Both p53 and p21 can have a function in the cellular senescence pathway (38, 39). We therefore examined protein expression levels of p53 and p21 over 8 days following an 8-hour treatment with MLN4924. Both p53 and p21 were induced 24 hour post-wash-out and their expression persisted thereafter for the entire time course (Fig. 6F). We then

performed the SA- β -gal staining assay in p53^{-/-} or p21^{-/-} HCT116 cells to determine the level of senescence in the absence of these proteins. As shown in Fig. 6G, the number of SA- β -gal stained cells was only half in the p21^{-/-} HCT116 compared to those of WT HCT116, indicating that p21 plays an important role in the senescence pathway. p53 appeared to be less essential than p21, which was consistent with results from other studies (40). The p16 gene is silenced in these cells (41), so the residual senescence in the p21^{-/-} cells was most likely by a p21- and p16- independent pathway.

p21 and p53 deficient HCT116 cells are more sensitive to transient treatment with MLN4924

Since transient exposure to MLN4924 causes both senescence and apoptosis, but senescence is attenuated in the p21^{-/-} cells, we could ask how important is the senescence for the toxicity of MLN4924 on cancer cells. We noticed that although p21- and p53-deficient cells exhibited less senescence after transient treatment with MLN4924, the total cell numbers observed were much less than in WT cells, which suggested that p53^{-/-} or p21^{-/-} HCT116 cells might be more susceptible to overall cell death or growth inhibition by MLN4924. Colony formation assays following an 8-hour treatment of MLN4924 in all three cell-lines confirmed this (Fig. 7A). Consistent with our previous results (Fig. 6B), colony formation was decreased by MLN4924 treatment in a dose-dependent manner in WT HCT116 cells, but the p53- and p21- deficient cells formed fewer colonies than WT cells, indicating that the absence of p53 or p21 sensitized the cells to the drug treatment. Since senescence is attenuated in the mutant cells (Fig. 6G), the result suggests that apoptosis pathways are important for cell killing after transient exposure to MLN4924.

We also performed an MTT cell growth assay to compare cell survival rate upon either transient or 72-hour continuous exposure to MLN4924. After 8-hour treatment, the IC_{50} for WT, p53^{-/-} and p21^{-/-} cells were 0.9 μ M, 0.18 μ M and 0.25 μ M, respectively (Fig. 7B), which was consistent with the results of the colony formation assays. However, the difference was much smaller upon 72-hour continuous exposure: IC_{50} of 0.08 μ M, 0.07 μ M and 0.07 μ M in WT, p53^{-/-} and p21^{-/-} cells, respectively (Fig. S4A).

To confirm that cells with mutant p53 were more susceptible to cell death by MLN4924, we performed MTT assay in MCF7 cells after MLN4924 transient exposure. After p53 knockdown, IC_{50} decreased from 0.68 μ M to 0.4 μ M (Fig 7B, S4B). Similar results were obtained when we compared IC_{50} in two lung cancer cells NCI-H23 (p53 mutant, IC_{50} 0.28 μ M) and NCI-H460 (wild type p53, IC_{50} 1.5 μ M) (Fig 7B). Intriguingly, when we compared IC_{50} in more than 20 cancer cell lines upon 72hr MLN4924 treatment, after dividing them into p53 WT (wild type) group and p53 MT (mutant) group, we found the median value of WT group was significantly higher than MT group (465nM vs. 280nM, Fig. S4C) despite all the different genetic backgrounds. It must be noted, however, that there are other genetic factors that affect MLN4924 sensitivity besides p53 status. For example we obtained opposite results when comparing MCF7 (WT p53) with MDA-MB-231 (MT p53) cells where the MCF7 cells were more susceptible to MLN4924 (Fig. S4D). Despite this exception, our data suggests that p53 mutant cells are generally more susceptible to MLN4924.

Thus there is a clear therapeutic advantage of transient MLN4924 treatment, particularly considering that the p53 mutant cells are more susceptible to cell death than

the p53 WT cells. Since up to 50% of human tumors have a mutant p53 gene, our results suggest that the kinetics of MLN4924 administration might alter the therapeutic index.

Discussion

As a potential anti-cancer drug, MLN4924 was discovered to inhibit NAE activity, inhibit cullins, increase the expression of CRL substrates, induce re-replication and cause cell death (21). In this paper, we demonstrated that the regulation of Cdt1 protein level is the rate-limiting step for the induction of re-replication upon MLN4924 treatment. It is noteworthy that even transient exposure of HCT116 colon cancer cells to MLN4924 leads to DNA re-replication. Once re-replication is induced, DNA damage checkpoint pathways are activated, which then lead to apoptosis and cellular senescence. We found that p53^{-/-} and p21^{-/-} HCT116 cells are both more sensitive to MLN4924 exposure than wild type cells, indicating that cancer cells with p53 mutations, are likely more susceptible to transient exposure to the drug.

Various CRL substrates accumulate upon MLN4924 treatment, including Cdt1, p27, NRF2(21) and possibly Cdc6 (Fig. S1C). However, our data suggests that the deregulation of Cdt1 protein level plays an essential role in DNA re-replication induction, demonstrated by the decline in re-replication when Cdt1 is knocked down. That depletion of Orc2, MCM7 and Cdc6 did not prevent re-replication should not be interpreted to say that pre-RC components are not required for re-replication. The more likely hypothesis is that these proteins are in vast excess and so do not become rate limiting for re-replication after siRNA depletion.

We noticed a high G2 peak and a residual 15% of cells re-replicating after MLN4924 treatment in Cdt1 depleted cells (Supplementary Fig. S1C). The 15% of cells

labeled as re-replicating could arise from the tail of the large G2/M peak observed and may not be real re-replication that leads to DNA damage, as there was no activation of either Chk1 or Chk2 in these cells (Fig. 1B). Taken together, these data show that MLN4924 cause a G2/M arrest, consistent with the report that siCdt2 can induce G2/M arrest (13). This hypothesis was further confirmed by the increased phosphorylation of Cdc2 on Y15 and the loss of phosphorylation of H3 on S10 in cells treated with MLN4924 (Supplementary Fig. S1E), indicating that cells cannot enter mitosis. None of these changes, increase in G2 population, increase in Cdc2-P-Y15, and decrease of H3 phosphorylation, were relieved by decreasing Cdt1. Thus unlike re-replication, the G2/M block seen with MLN4924 may be due to stabilization of substrates other than Cdt1.

In vivo data suggested that Cdt1 protein level peaked at 2-4 hours after injection of MLN4924 into tumor-bearing mice and started to decrease by 4-8 hours post-injection (21). Therefore we wished to evaluate the effect of transient exposure of cancer cells to MLN4924. Amazingly even one-hour exposure was sufficient to induce re-replication in 40% of a colon cancer cell population in culture. With short treatment, we discovered that S phase cells were more susceptible to MLN4924 induced re-replication, which is consistent with the idea that S phase cells have already licensed origins (and fired many of them), so that relicensing by transient stabilization of Cdt1 would cause re-replication. The observations that transient exposure can lead to re-replication and S phase cells are more susceptible to this exposure are positive indicators for the clinical usefulness of this compound.

In addition to activation of apoptosis, we observed activation of senescence pathway after transient exposure of MLN4924. As previously stated, this was not due to a

reduction in re-replication, as HCT116 cells displayed an equivalent increase in cells with a >4N DNA content even after short treatment with MLN4924 compared to continuous treatment (Fig. 3). This re-replication subsequently led to DNA damage and activated checkpoint and apoptosis pathways (Fig. 5). Unexpectedly, we observed that the senescence phenotype did not appear in continuously treated cells (Fig. 6A). Although there was barely any difference in the extent of re-replication between the two treatments, DNA damage signals (DDS) were possibly different, resulting in a different choice of cell fate between apoptosis and senescence (42). Upon short exposure, no new DDS occurred from persistent origin re-firings, which likely occurred in the continuously treated cells. This lower level of DNA damage signaling perhaps is not great enough in duration or extent to trigger cells apoptosis, though it is sufficient to induce p21 and p53.

One remaining question is what activates senescence. Is it related to re-replication induced DNA damage? Previous papers suggested DNA damage caused by re-replication could activate the senescence pathway (37, 43, 44). In our hands, depletion of Geminin or Emi1 in HCT116 cells similarly induced senescence after 3-4 days (data not shown). Consistent with this idea, decrease in re-replication by depletion of Cdt1 reduced cellular senescence (Fig. 6E). Thus the senescence is triggered by the re-replication induced DNA damage. Another intriguing question is, once cell fate has been determined, is it reversible? We treated cells with Z-VAD-FMK together with MLN4924 to inhibit cells from entering apoptosis (Supplementary Fig. S3). However, there was no significant increase in senescence, which suggested an irreversible commitment to apoptotic, non-senescent pathways.

It has already been suggested that p53 and p21 level are increased during cellular senescence (45, 46). Multiple studies have shown that the p53-p21 pathway is critical for senescence to occur in human fibroblasts and cancer cells (38, 42, 47, 48). However, some researchers have observed that although p53 and p21 are positive factors in senescence they are not necessary (49). Our results suggest that p53 and p21 have important functions in initiating cellular senescence upon MLN4924 treatment in tumor cells, but they are dispensable given that p53^{-/-} or p21^{-/-} cells showed decreased but not absent SA-β-gal staining (Fig. 6G).

Although both p53^{-/-} and p21^{-/-} HCT116 cells underwent less senescence than WT cells, both were more susceptible to cell death after transient treatment with MLN4924 (Fig. 7), suggesting a shifting of the balance towards a more apoptotic phenotype upon intermittent treatment in those cells. This p53-independent susceptibility to MLN4924 is potentially critical for clinical applications, where nearly half of human tumors have mutated their p53 gene. Conventional chemotherapy is less effective in p53 mutant cells. Thus MLN4924 is exceptional in its ability to target p53 mutant tumors.

Acknowledgments

We are grateful to Dr. Fred Bunz for providing us isogenic p21^{-/-} and p53^{-/-} HCT116 cells. We wish to thank members of the Dutta lab for reading the manuscript and helpful discussions.

Reference

1. Bell SP, Dutta A. DNA replication in eukaryotic cells. *Annu Rev Biochem* 2002;71:333-74.
2. Bell SP, Stillman B. ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. *Nature* 1992;357:128-34.
3. Dutta A, Bell SP. Initiation of DNA replication in eukaryotic cells. *Annu Rev Cell Dev Biol* 1997;13:293-332.

4. Lei M, Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. *J Cell Sci* 2001;114:1447-54.
5. Maiorano D, Moreau J, Mechali M. XCDT1 is required for the assembly of pre-replicative complexes in *Xenopus laevis*. *Nature* 2000;404:622-5.
6. Nishitani H, Lygerou Z, Nishimoto T, Nurse P. The Cdt1 protein is required to license DNA for replication in fission yeast. *Nature* 2000;404:625-8.
7. Arias EE, Walter JC. Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. *Genes Dev* 2007;21:497-518.
8. Kim Y, Kipreos ET. Cdt1 degradation to prevent DNA re-replication: conserved and non-conserved pathways. *Cell Div* 2007;2:18.
9. Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Walter JC, Dutta A. Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. *Science* 2000;290:2309-12.
10. Tada S, Li A, Maiorano D, Mechali M, Blow JJ. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. *Nat Cell Biol* 2001;3:107-13.
11. Machida YJ, Hamlin JL, Dutta A. Right place, right time, and only once: replication initiation in metazoans. *Cell* 2005;123:13-24.
12. Zhu W, Chen Y, Dutta A. Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. *Mol Cell Biol* 2004;24:7140-50.
13. Jin J, Arias EE, Chen J, Harper JW, Walter JC. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. *Mol Cell* 2006;23:709-21.
14. Zhong W, Feng H, Santiago FE, Kipreos ET. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. *Nature* 2003;423:885-9.
15. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. *J Biol Chem* 1999;274:12036-42.
16. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. *Nat Rev Mol Cell Biol* 2005;6:9-20.
17. Read MA, Brownell JE, Gladysheva TB, et al. Nedd8 modification of cul-1 activates SCF(beta-TrCP)-dependent ubiquitination of I kappa B alpha. *Mol Cell Biol* 2000;20:2326-33.
18. Chiba T, Tanaka K. Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. *Curr Protein Pept Sci* 2004;5:177-84.
19. Petroski MD. Mechanism-based neddylation inhibitor. *Chem Biol*;17:6-8.
20. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. *Mol Cell*;37:102-11.
21. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* 2009;458:732-6.
22. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* 1998;282:1497-501.
23. Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. *Genes Dev* 2008;22:2496-506.

24. Lin JJ, Dutta A. ATR pathway is the primary pathway for activating G2/M checkpoint induction after re-replication. *J Biol Chem* 2007;282:30357-62.
25. Montes de Oca R, Andreassen PR, Margossian SP, et al. Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. *Blood* 2005;105:1003-9.
26. Zhu W DA. An ATR- and BRCA1-Mediated Fanconi Anemia Pathway Is Required for Activating the G2/M Checkpoint and DNA Damage Repair upon Rereplication. *MCB* 2006;26.
27. Dhar SK, Yoshida K, Machida Y, et al. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. *Cell* 2001;106:287-96.
28. Sugimoto N, Tatsumi Y, Tsurumi T, et al. Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding. *J Biol Chem* 2004;279:19691-7.
29. Takeda DY, Parvin JD, Dutta A. Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase. *J Biol Chem* 2005;280:23416-23.
30. Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. *J Biol Chem* 2003;278:30854-8.
31. Hu J, McCall CM, Ohta T, Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. *Nat Cell Biol* 2004;6:1003-9.
32. Senga T, Sivaprasad U, Zhu W, et al. PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination. *J Biol Chem* 2006;281:6246-52.
33. Sansam CL, Shepard JL, Lai K, et al. DTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint. *Genes Dev* 2006;20:3117-29.
34. McGarry TJ. Geminin deficiency causes a Chk1-dependent G2 arrest in *Xenopus*. *Mol Biol Cell* 2002;13:3662-71.
35. Stein GH, Beeson M, Gordon L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. *Science* 1990;249:666-9.
36. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A* 1995;92:9363-7.
37. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 2006;444:638-42.
38. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 1997;88:593-602.
39. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. *Mol Cell Biol* 1999;19:2109-17.
40. Zou X, Ray D, Aziyu A, et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. *Genes Dev* 2002;16:2923-34.
41. Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. *Cancer Res* 1998;58:591-3.
42. Han Z, Wei W, Dunaway S, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. *J Biol Chem* 2002;277:17154-60.

43. Liontos M, Koutsami M, Sideridou M, et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. *Cancer Res* 2007;67:10899-909.
44. Verschuren EW, Ban KH, Masek MA, Lehman NL, Jackson PK. Loss of Emi1-dependent anaphase-promoting complex/cyclosome inhibition deregulates E2F target expression and elicits DNA damage-induced senescence. *Mol Cell Biol* 2007;27:7955-65.
45. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. *Proc Natl Acad Sci U S A* 1996;93:13742-7.
46. Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. *Proc Natl Acad Sci U S A* 1995;92:8348-52.
47. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. *Science* 1997;277:831-4.
48. Kang JY, Kim JJ, Jang SY, Bae YS. The p53-p21(Cip1/WAF1) pathway is necessary for cellular senescence induced by the inhibition of protein kinase CKII in human colon cancer cells. *Mol Cells* 2009;28:489-94.
49. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. *Drug Resist Updat* 2001;4:303-13.

Figure Legends

Figure 1. Cdt1 protein level is important for MLN4924 induced re-replication in HCT116 cells

(A) HCT116 cells were transfected twice with siGL2 or siCdt1 at 0- and 24-hour time point and incubated for a total of 48 hours before the addition of 0.3 μ M MLN4924 or DMSO. Cells were harvested for PI FACS after 20 hours of treatment. The percentage of cells containing >4N DNA was shown. (B) Total cell lysates from (A) were blotted with indicated protein antibodies. (*: non-specific band) (C) HCT116 WT or e83 cells were treated with DMSO or 0.3 μ M MLN4924 for 20 hours before harvested for FACS. The percentage of cells containing >4N DNA was shown. (D) Similar assay as described in (A) was performed with siMcm7. The percentage of cells containing >4N DNA was shown. (E) Similar assay as in (A) was performed with siCdc6.

Figure 2. MLN4924 induces re-replication through inhibition of CRL4^{Cdt2}

(A) HCT116 cells were transfected with GL2, Cdt2, Geminin siRNA and treated with MLN4924 as described in Fig. 1(A). Cell lysates were harvested and blotted with indicated antibodies. (B) DNA contents of the cells treated in (A) were determined using FACS and plotted in horizontal bar graph. Representative FACS data from siGL2 treated cells indicating different DNA contents measured.

Figure 3. Transient exposure to MLN4924 induces re-replication in HCT116 cells

(A) HCT116 cells were treated with DMSO or 1 μ M MLN4924 for indicated hours. Cells were washed with PBS twice, incubated in fresh medium and harvested 24 hours after initial addition of the chemicals. Percentage of cells containing >4N DNA contents was plotted. (B) HCT116 cells were treated with DMSO or 1 μ M MLN4924 for 4 hours. Cells were then washed and harvested at 0, 2, 4 and 20 hours after the wash-out as indicated. Cell lysates were blotted with Cdt1 or Actin antibodies.

Figure 4. S phase cells are more susceptible to MLN4924 induced re-replication

(A) Schematic of experimental procedures of (B) to (D). (B) FACS profiles of control samples harvested at indicated time points. (C) Total lysates from cells harvested 20 hours after the drug wash-out were blotted with indicated antibodies. (D) FACS profiles from above cells were shown. The percentage of cells with >4N DNA is plotted in the bar graphs below. (E) Schematic of experiment of (F). (F) FACS profiles were shown as indicated. (Dashed line: DMSO; solid line: MLN4924) Percentages of re-replicating cells after MLN4924 treatment are indicated.

Figure 5. Both checkpoint and apoptosis pathways are activated upon short exposure of cells to MLN4924

(A) HCT116 cells were treated with DMSO, 1 μ M or 3 μ M MLN4924 for 8 hours. Cells were harvested 24 or 72 hours after the drug wash-out. Cell lysates were blotted with indicated protein antibodies. (*: nonspecific band) (B) Cells from above were harvested for PI FACS. Percentages of cells containing <2N (left) or >4N DNA (right) are shown.

Figure 6. The senescence pathway is induced in HCT116 cells after transient exposure to MLN4924

(A) HCT116 cells were treated with 1 μ M MLN4924 continuously (top panel) or only for 8 hours (middle and lower panels). Movie images of the cells at indicated time points are shown. (B) HCT116 cells were treated as described in the text. Cell survival rate in the colony formation assay is shown. Error bar represents three independent experiments. (C) HCT116 cells were treated with 1 μ M MLN4924 for indicated hours before wash-out. SA β -Gal staining assay was then performed after 72 hours. Positive stained cells were counted and plotted as percentage of total cell numbers. Mean \pm standard deviation of three different experiments. (D) Representative SA- β -gal staining for indicated samples. (E) HCT116 cells were transfected twice with siGL2 or siCdt1 as described in Figure 1(A). 48 hours after initial transfection, cells were treated with 1 μ M MLN4924 for 8 hours. Cells were either harvested for FACS analysis after 24 hours, or subjected to SA- β -gal staining assay after 72 hours. (F) HCT116 cells were treated with 1 μ M MLN4924 8 hours. Cells were harvested for western blots of p53 and p21 at different time points after wash-out. (G) HCT116 WT, p53^{-/-} or p21^{-/-} cells were treated with 1 μ M MLN4924 for 8 hours. SA- β -gal staining assay was performed 72

hours after the wash-out. Percentage of positive stained cells is shown. Mean±standard deviation of 3 experiments. * indicates statistical significance ($p<0.01$).

Figure 7. p53 mutant cells are susceptible to transient treatment with MLN4924

(A) HCT116 WT, p53^{-/-} or p21^{-/-} cells were treated with 0, 0.1, 0.3, 0.9, 1.8 or 2.7 μ M of MLN4924. Cell survival rates were measured as described in Figure 6(B). Mean and standard deviation from triplicates. * indicates statistical significance ($p<0.01$).

(B) Viable HCT116, MCF7 (MLN4924 treatment 24hrs after control or p53 siRNA), H460 and H23 cells after 8hr MLN4924 treatment at different doses were measured using MTT assay as described. The points indicate mean and standard deviation of triplicates. * indicates statistically significant difference at various MLN4924 concentrations between the two cell lines ($p<0.01$).




Figure 1. Cdt1 protein level is important for MLN4924 induced re-replication in HCT116 cells

(A) HCT116 cells were transfected twice with siGL2 or siCdt1 at 0- and 24-hour time point and incubated for a total of 48 hours before the addition of 0.3 μ M MLN4924 or DMSO. Cells were harvested for PI FACS after 20 hours of treatment. The percentage of cells containing >4N DNA was shown. (B) Total cell lysates from (A) were blotted with indicated protein antibodies. (*: non-specific band) (C) HCT116 WT or e83 cells were treated with DMSO or 0.3 μ M MLN4924 for 20 hours before harvested for FACS. The percentage of cells containing >4N DNA was shown. (D) Similar assay as described in (A) was performed with siMcm7. The percentage of cells containing >4N DNA was shown. (E) Similar assay as in (A) was performed with siCdc6.

Fig. 2




Figure 2. MLN4924 induces re-replication through inhibition of CRL4Cdt2
 (A) HCT116 cells were transfected with GL2, Cdt2, Geminin siRNA and treated with MLN4924 as described in Fig. 1(A). Cell lysates were harvested and blotted with indicated antibodies. (B) DNA contents of the cells treated in (A) were determined using FACS and plotted in horizontal bar graph. Representative FACS data from siGL2 treated cells indicating different DNA contents measured.




Figure 3. Transient exposure to MLN4924 induces re-replication in HCT116 cells

(A) HCT116 cells were treated with DMSO or $1\mu\text{M}$ MLN4924 for indicated hours. Cells were washed with PBS twice, incubated in fresh medium and harvested 24 hours after initial addition of the chemicals. Percentage of cells containing $>4\text{N}$ DNA contents was plotted. (B) HCT116 cells were treated with DMSO or $1\mu\text{M}$ MLN4924 for 4 hours. Cells were then washed and harvested at 0, 2 and 4 hours after the wash-out as indicated. Cell lysates were blotted with Cdt1 or Actin antibodies.




Figure 4. S phase cells are more susceptible to MLN4924 induced re-replication

(A) Schematic of experimental procedures of (B) to (D). (B) FACS profiles of control samples harvested at indicated time points. (C) Total lysates from cells harvested 20 hours after the drug wash-out were blotted with indicated antibodies. (D) FACS profiles from above cells were shown. The percentage of cells with >4N DNA is plotted in the bar graphs below. (E) Schematic of experiment of (F). (F) FACS profiles were shown as indicated. (Dashed line: DMSO; solid line: MLN4924) Percentages of re-replicating cells after MLN4924 treatment are indicated.




Figure 5. Both checkpoint and apoptosis pathways are activated upon short exposure of cells to MLN4924 (A) HCT116 cells were treated with DMSO, 1 μ M or 3 μ M MLN4924 for 8 hours. Cells were harvested 24 or 72 hours after the drug wash-out. Cell lysates were blotted with indicated protein antibodies. (*: nonspecific band) (B) Cells from above were harvested for PI FACS. Percentages of cells containing <2N (left) or >4N DNA (right) are shown.




Figure 6. The senescence pathway is induced in HCT116 cells after transient exposure to MLN4924 and p21 plays an important role in the induction

(A) HCT116 cells were treated with 1 μ M MLN4924 continuously (top panel) or only for 8 hours (middle and lower panels). Movie images of the cells at indicated time points are shown. (B) HCT116 cells were treated as described in the text. Cell survival rate in the colony formation assay is shown. Error bar represents three independent experiments. (C) HCT116 cells were treated with 1 μ M MLN4924 for indicated hours before wash-out. SA β -Gal staining assay was then performed after 72 hours. Positive stained cells were counted and plotted as percentage of total cell numbers. Mean \pm standard deviation of three different experiments. (D) Representative SA- β -gal staining for indicated samples. (E) HCT116 cells were transfected twice with siGL2 or siCdt1 as described in Figure 1(A). 48 hours after initial transfection, cells were treated with 1 μ M MLN4924 for 8 hours. Cells were either harvested for FACS analysis after 24 hours, or subjected to SA- β -gal staining assay after 72 hours. (F) HCT116 cells were treated with 1 μ M MLN4924 8 hours. Cells were harvested for western blots of p53 and p21 at different time points after wash-out. (G) HCT116 WT, p53^{-/-} or p21^{-/-} cells were treated with 1 μ M MLN4924 for 8 hours. SA- β -gal staining assay was performed 72 hours after the wash-out. Percentage of positive stained cells is shown. Mean \pm standard deviation of 3 experiments. * indicates statistical significance ($p < 0.01$).




Figure 7. p53 mutant cells are susceptible to transient treatment with MLN4924

(A) HCT116 WT, p53^{-/-} or p21^{-/-} cells were treated with 0, 0.1, 0.3, 1 μM of MLN4924. Cell survival rates were measured as described in Figure 6(B). Mean and standard deviation from triplicates. * indicates statistical significance (p<0.01). (B) Viable HCT116, MCF7 (MLN4924 treatment 24hr after control or p53 siRNA), H460 and H23 cells after 8hr MLN4924 treatment at different doses were measured using MTT assay as described. The points indicate mean and standard deviation of triplicates. * indicates statistically significant difference at various MLN4924 concentrations between the two cell lines (p<0.01).

2. Biographical Sketch

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Jie Lin	POSITION TITLE Graduate Student		
eRA COMMONS USER NAME JLin			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Fudan University, Shanghai, China	B.S.	1997-2001	Biology
University of Virginia, Charlottesville, VA	Ph.D.	2003-2011	Biochemistry and Molecular Genetics

Please refer to the application instructions in order to complete sections A, B, and C of the Biographical Sketch.

A. Positions and Honors.

10/1997 Scholarship for freshman in Fudan University, Shanghai, China
04/2000 – 07/2001 undergraduate, in the State Key Laboratory of Genetic Engineering at Fudan University
01/2001 People's Scholarship in Fudan University, Shanghai, China
08/2001 – 07/2003 Research Assistant, in the Division of Genetics, Chinese National Human Genome Center at Shanghai
08/2003 – 05/2011 Graduate student, in Anindya Dutta Lab, University of Virginia

B. Publications (in chronological order).

Chen H, Tang X, **Lin J**, Zhang B, Ren D, **Community Constitute and Phylogenetic Analysis on Soil Uncultured Microorganism**. *Acta Microbiologica Sinica*. 2002, 42 (4): 478 – 483

Chen HK, Liu XQ, **Lin J**, Chen TY, Feng QS, Zeng YX, **Lack of mutation in coding region of hCDC4 gene in human nasopharyngeal carcinoma**. *Tumor Journal of the World*. 2002, 1(21): 16-18

Chen HK, Liu XQ, **Lin J**, Chen TY, Feng QS, Zeng YX, **Mutation analysis of KLF6 gene in human nasopharyngeal carcinoma**. *Chinese Journal of Cancer*. 2002, 21 (10): 1047-1050.

Lin JJ, Dutta A: **ATR pathway is the primary pathway for activating G2/M checkpoint induction after re-replication**. *J Biol Chem* 2007, **282**:30357-30362.


Hook SS, **Lin JJ**, Dutta A: **Mechanisms to control rereplication and implications for cancer.** *Curr Opin Cell Biol* 2007, 19:663-671

Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8 targeting drug MLN4924 elicits DNA re-replication by stabilizing Cdt1 in S Phase, triggering checkpoint activation, apoptosis and senescence in cancer cells. *Cancer Research*. 2010, 70 (24): 10310-20

Supporting Data

Fig. 1

A.



B.






Fig. 2

A.



B.



C.






Fig. 3

A.



B.



C.




Figure Legends

Fig. 1 Both p21 and p53 are important but not essential in activating senescence pathway after re-replication.

(A) HCT116 cells were treated with 1 μ M MLN4924 8 hours. Cells were harvested for western blots of p53 and p21 at different time points after wash-out.

(B) HCT116 WT, p53^{-/-} or p21^{-/-} cells were treated with 1 μ M MLN4924 for 8 hours. SA- β -gal staining assay was performed 72 hours after the wash-out. Percentage of positive stained cells is shown. Mean \pm standard deviation of 3 experiments. * indicates statistical significance ($p < 0.01$).

Fig. 2 p21 and p53 deficient cells are more sensitive to transient treatment with MLN4924

(A) HCT116 WT, p53^{-/-} or p21^{-/-} cells were treated with 0, 0.1, 0.3, or 1 μ M of MLN4924. Cell survival rates were measured by colony formation assay. Mean and standard deviation from triplicates. * indicates statistical significance ($p < 0.01$).

(B) Viable cells (as indicated) after 8hr MLN4924 treatment at different doses were measured using MTT assay. (C) Viable HCT116 cells after 72hr MLN4924 treatment at different doses were measured using MTT assay. For (B) and (C) the points indicate mean and standard deviation of triplicates. * indicates statistically significant difference at various MLN4924 concentrations between the WT and the mutant cells ($p < 0.01$).

Fig. 3 P53 is an important factor to affect MLN4924 induced cell death

(A) MCF7 cells were transfected with siGL2 or siP53 36 hours before MLN4924 exposure. Cell lysates were harvested before MLN4924 treatment and blotted with p53 and actin. These are the cells used in Fig. 2B.

(B) 3,000–8,000 cells were seeded per well in 96-well culture plates and incubated overnight at 37°C. MLN4924 was added to the cells and incubated for 72 hours. Cell viability was determined using the ATPlite assay. Median values were indicated with lines. The cells are classified based on their p53 status: wild type or mutant.

(C)) Viable MCF7 (p53 WT) and MDA-MB-231 (p53 mutant) cells after 8hr MLN4924 treatment at different doses were measured using MTT assay. The points indicate mean and standard deviation of triplicates.